Chongqing Pharscin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002907.SZ

Chongqing Pharscin Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: 153.52

Chongqing Pharscin Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) is 153.52 on January 27, 2025, a -14.44% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Chongqing Pharscin Pharmaceutical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 196.44 on May 14, 2024, which is 27.96% above the current Price to Earnings Ratio (P/E).
  • Chongqing Pharscin Pharmaceutical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 132.63 on February 05, 2024, which is -13.60% below the current Price to Earnings Ratio (P/E).
  • Chongqing Pharscin Pharmaceutical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 166.95.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
SV Wall Street
Shenzhen Stock Exchange: 002907.SZ

Chongqing Pharscin Pharmaceutical Co., Ltd.

CEO Ms. Xiaoying Liu
IPO Date Oct. 20, 2017
Location China
Headquarters No. 89, Middle Sec of Huangshan Ave
Employees 1,411
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies
Description

Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, and API synthesis. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases. Chongqing Pharscin Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Chongqing, China.

StockViz Staff

February 3, 2025

Any question? Send us an email